Clinical Trials Logo

Clinical Trial Summary


- ECI301 is a drug that may help make cancer cells more visible to the immune system after radiation. The drug may also help the immune system destroy the cancer at sites that have not received radiation therapy. Researchers want to study ECI301 in people with advanced cancer or cancer that has spread in the body (metastatic).


- To test ECI301 with radiation therapy for advanced or metastatic cancer.


- People at least 18 years of age with either metastatic or advanced cancer that may benefit from radiation therapy.


- Participants will be screened with a medical history and physical exam. They will also have blood and urine tests, and imaging studies.

- All participants will have radiation therapy 5 days a week for 2 weeks.

- They will have different doses of ECI301 to test its safety and effectiveness. ECI301 will be given in a vein during the second week of radiation therapy. Frequent blood tests and imaging studies will monitor the treatment.

- After participants have ECI301, tumor samples may be taken from the site that had radiation and another site that did not have radiation.

- Followup visits will include blood tests and imaging studies.

Clinical Trial Description


- Patients with metastatic or locally advanced cancer frequently require palliative radiotherapy to relieve symptoms; however, progression of disease is frequent in patients with extended survival

- Radiation results in tumor cell death which can result in increased dendritic cell activation and trafficking

- ECI301 is a derivative of Macrophage Inflammatory Protein-1?, a 70 amino acid chemokine that is a ligand for CCR1 and CCR5, the chemokine receptors of immature dendritic cells.

- ECI301 has been shown to enhance the effect of radiotherapy in animal models.


- The primary objective is to determine the maximum tolerated dose (MTD) of ECI301 delivered in combination with 30 Gy of external beam radiation to patients with metastatic or locally advanced cancer.

- The secondary objectives are:

- To describe the safety and tolerability of ECI301 delivered in combination with 30 Gy of external beam radiation to patients with metastatic or locally advanced cancer

- To evaluate the humoral and cellular immune responses by:

- Measurement of circulating precursor dendritic cells before and after the completion of ECI301

- Measurement of circulating MIP-? before and after the completion of ECI301

- Assessment of T-lymphocyte quantitative and qualitative changes by flow cytometry and assays for IFN? production

- To define pharmacologic parameters following the intravenous dose of ECI301

- To determine if neutralizing anti-EC301 antibodies occur after treatment

- To describe the response at the radiated site and distant sites after radiation in combination with ECI301


- Age >18 years.

- ECOG performance status <2.

- Life expectancy of greater than 3 months

- Histologically confirmed metastatic or locally advanced cancer for which radiotherapeutic management would be appropriate

- No recent history of myocardial infarction or unstable angina


- This is a Phase I trial to determine the maximum tolerated dose of ECI301 in combination with external beam radiation therapy in patients with locally advanced or metastatic solid tumors.

- Patients will be treated with radiation therapy in a standard manner with ECI301 given daily during radiation. The dose of ECI301 will be escalated over the course of the trial to determine the MTD of daily ECI301 in combination with radiotherapy.

- We anticipate that accrual to this trial of 30 patients will take approximately 2 years. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT01441115
Study type Interventional
Source National Institutes of Health Clinical Center (CC)
Status Terminated
Phase Phase 1
Start date September 6, 2011
Completion date April 24, 2013

See also
  Status Clinical Trial Phase
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Active, not recruiting NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT01077414 - Phenomenological Study of Psycho-Socio-Spiritual Healing in the Context of Chronic or Life-Threatening Illness
Completed NCT01340846 - A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors Phase 1
Recruiting NCT02565004 - Clinical and Laboratory Analysis of Familial Cancer
Active, not recruiting NCT02502396 - Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center N/A
Not yet recruiting NCT03662061 - Assessment of a Multidisciplinary Team Meeting (RCP) in Geriatric Oncology
Completed NCT03272880 - Utilizing the Arts to Improve Health, Resilience, and Well-Being Among Cancer Patients and Their Caregivers N/A
Active, not recruiting NCT00587886 - Estrogen, Diet, Genetics and Endometrial Cancer
Recruiting NCT03548077 - POWERPLAY: Promoting Men's Health at Work N/A
Completed NCT03503838 - A Pilot Study of Online Yoga for MPN Patients N/A
Completed NCT00984035 - Investigation of Cisplatin-Related Kidney Toxicity
Completed NCT01447186 - Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men N/A
Not yet recruiting NCT03257969 - Impact of the DROP Program on the DRP (Drug Related Problems) Related to Oral Anticancer Drugs in Ambulatory Patients With Risk Factors N/A
Recruiting NCT02883699 - Individually Tailored Training Prescriptions in Cancer Patients: The TOP Study N/A
Recruiting NCT02869802 - Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis